Stock comparison
Arbutus Biopharma
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABUS
Arbutus Biopharma
Market cap
$859.29M
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Arbutus Biopharma ABUS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABUS | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 49D | 65C | GMAB |
| Benjamin Graham | 43D | 64C | GMAB |
| Philip Fisher | 55C | 48D | ABUS |
| Peter Lynch | 48D | 25F | ABUS |
| Joel Greenblatt | 100A | 76B | ABUS |
| Charlie Munger | 64D | 68C | GMAB |
| Terry Smith | 66B | 71C | GMAB |
Side-by-side metrics
| Metric | ABUS | GMAB |
|---|---|---|
| Market cap | $859.29M | $16.5B |
| P/E (TTM) | 5.1x | 6.2x |
| EV/EBIT | - | 12.0x |
| ROIC (TTM) | 56.72% | 43.78% |
| Gross margin | 99.98% | 93.88% |
| Net margin | 83.95% | 18.23% |
| Revenue CAGR 5y | 6.4% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | 0.0x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABUS leads on
- EV/EBIT-vs 12.0x+140%
- Revenue CAGR 5y6.4%vs -18.45%+135%
- Debt / Equity0.0xvs 0.1x+97%
- Net margin83.95%vs 18.23%+78%
GMAB leads on
- Market cap$16.5Bvs $859.29M+95%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.